Abstract: The invention relates to targeting of diagnostic agents by use of lipid-based compositions. The invention is useful in the diagnosis of various disorders which are associated with or resulting from increased levels of extracellular PLA2 activity in the diseased tissue, e.g. cancer, infectious, and inflammatory conditions.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
May 6, 2008
Assignee:
Liplasome Pharma A/S
Inventors:
Kent Jørgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frøkjær, Ole G. Mouritsen
Abstract: The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which causes an elevated PLA2 level in the infected mammal. Preferred parasitic infection are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.
Type:
Application
Filed:
December 12, 2006
Publication date:
June 14, 2007
Applicant:
LiPlasome Pharma A/S
Inventors:
Kent Jorgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frokjer, Ole Mouritsen
Abstract: The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which cause an elevated PLA2 level in the infected mammal. Preferred parasitic infections are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
January 23, 2007
Assignee:
LiPlasome Pharma A/S
Inventors:
Kent Jørgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frøkjer, Ole G. Mouritsen
© 2025 Justia
